This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration.

Array Technologies (NASDAQ:ARRY) +2.6% in Wednesday's trading as Janney initiated coverage with a Buy rating and $37 price target, saying investment tax credits "provide a path to significant ...